AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the
“Company”), a national provider of premium body contouring
procedures, today announced results for the second quarter ended
June 30, 2023.
- Cases increased
13.4% over the prior year period to 4,186
|
- Revenue
increased 12.2% over the prior year to $55.7 million
|
- Net income of
$1.8 million for the quarter compared to $0.6 million in the prior
year period
|
- Diluted income
per share for the quarter of $0.03
|
- Diluted
adjusted net income per share for the quarter of $0.13
|
- Cash flow from
operating activities of $12.2 million
|
- Opened second
international center in London
|
"I am pleased with our performance for the second quarter and
for the first half of the year,” said Todd Magazine, Chief
Executive Officer of AirSculpt Technologies. "Our 13.4% case growth
continues to reflect the significant demand for AirSculpt’s
minimally invasive and permanent solution to body transformation.
We have opened four new centers this year, including our flagship
London location. All new centers are meeting or beating our
expectations. We expect to open our fifth center late in the third
quarter, which is in line with what we had planned. We continue to
see positive momentum and are well-positioned to deliver strong
growth in the back half of 2023.”
Second Quarter 2023 Results
Case volume was 4,186 for the second quarter of 2023,
representing growth of 13.4% over the prior year period case volume
of 3,691. Revenue for the second quarter of 2023 increased by 12.2%
to $55.7 million from $49.7 million in the prior year period. Net
income for the quarter was $1.8 million compared to $0.6 million in
the prior year period. The Company’s adjusted EBITDA for the
quarter was $14.6 million compared to $14.0 million for the prior
year period. For the three months ended June 30, 2023 and
2022, pre-opening de novo and relocation costs were $1.4 million
and $1.2 million, respectively.
Year to Date 2023 Results
Case volume was 7,826 for year to date 2023, representing growth
of 14.3% over the prior year case volume of 6,847. Revenue for 2023
increased by 13.8% to $101.5 million from $89.2 million in the
prior year period. Year to date net income/(loss) for 2023
increased to $1.8 million compared to $(0.1) million from the prior
year period. For the six months ended June 30, 2023, the Company’s
adjusted EBITDA was $24.1 million compared to $22.9 million for the
prior year period. For the six months ended June 30, 2023 and
2022, pre-opening de novo and relocation costs were $2.7 million
and $2.1 million, respectively.
2023 Outlook
The Company projects full year 2023 revenue and adjusted EBITDA
guidance as follows and expects to perform at the higher end of
both revenue and Adjusted EBITDA ranges:
- Revenues in a range of $187 to $192
million
- Adjusted EBITDA in a range of $43 to $45 million
- Adjusted EBITDA to cash flow from operations conversion ratio
of approximately 65% (1)
- Five new center openings
Pre-opening costs are projected to be approximately $5 million
for the full year 2023. The Company has opened four centers and
expects to open one additional center in the third quarter of 2023
bringing the total of new openings to five and achieving the full
year target for center openings. For additional information on
forward-looking statements, see the section titled "Forward-Looking
Statements" below.
(1) Calculated as cash flow from operating activities divided by
Adjusted EBITDA.
Liquidity
As of June 30, 2023, the Company had $20.8 million in cash
and cash equivalents and $5.0 million of borrowing capacity under
its revolving credit facility. The Company generated $12.2 million
and $18.5 million in operating cash flow for the three and six
months ended June 30, 2023, compared to $10.4 million and
$17.5 million for the same periods of 2022.
Conference Call Information
AirSculpt will hold a conference call today, August 11,
2023 at 8:30 am (Eastern Time). The conference call can be accessed
by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779
(international) using the conference ID 13739710 or by visiting the
link below to request a return call for instant telephone access to
the event.
https://callme.viavid.com/viavid/?callme=true&passcode=13725116&h=true&info=company&r=true&B=6
The live webcast may be accessed via the investor relations
section of the AirSculpt Technologies website at
https://investors.elitebodysculpture.com. A replay of the webcast
will be available for approximately 90 days following the call.
To learn more about AirSculpt Technologies, please visit the
Company's website at https://investors.elitebodysculpture.com.
AirSculpt Technologies uses its website as a channel of
distribution for material Company information. Financial and other
material information regarding AirSculpt Technologies is routinely
posted on the Company's website and is readily accessible.
About AirSculpt
AirSculpt is an experienced, fast-growing national provider of
body contouring procedures delivering a premium consumer experience
under its brand, Elite Body Sculpture. At Elite Body Sculpture, we
provide custom body contouring using our proprietary AirSculpt®
method that removes unwanted fat in a minimally invasive procedure,
producing dramatic results. It is our mission to generate the best
results for our patients.
Forward-Looking Statements
This press release contains forward-looking statements. In some
cases, you can identify these statements by forward-looking words
such as “may,” “might,” “will,” “should,” “expects,” “plans,”
“anticipates,” “believes,” “estimates,” “predicts,” “potential” or
“continue,” the negative of these terms and other comparable
terminology. These forward-looking statements, which are subject to
risks, uncertainties, and assumptions about us, may include
projections of our future financial performance, our anticipated
growth strategies, and anticipated trends in our business. These
statements are only predictions based on our current expectations
and projections about future events. There are important factors
that could cause our actual results, level of activity,
performance, or achievements to differ materially from the results,
level of activity, performance or achievements expressed or implied
by the forward-looking statements, including those factors
discussed in the section titled “Risk Factors” in our Annual Report
on Form 10-K.
Our future results could be affected by a variety of other
factors, including, but not limited to, failure to open and operate
new centers in a timely and cost-effective manner; inability to
open new centers due to rising interest rates and increased
operating expenses due to rising inflation; shortages or quality
control issues with third-party manufacturers or suppliers;
competition for surgeons; litigation or medical malpractice claims;
inability to protect the confidentiality of our proprietary
information; changes in the laws governing the corporate practice
of medicine or fee-splitting; changes in the regulatory, economic
and other conditions of the states and jurisdictions where our
facilities are located; and business disruption or other losses
from war, pandemic, terrorist acts or political unrest.
The risk factors discussed in “Risk Factors” in our Annual
Report on Form 10-K could cause our results to differ materially
from those expressed in the forward-looking statements made in this
press release.
There also may be other risks that are currently unknown to us
or that we are unable to predict at this time.
Although we believe the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee
future results, level of activity, performance, or achievements.
Moreover, neither we nor any other person assumes responsibility
for the accuracy and completeness of any of these forward-looking
statements. Forward-looking statements speak only as of the date
they were made, and we are under no duty to update any of these
forward-looking statements after the date of this press release to
conform our prior statements to actual results or revised
expectations.
Use of Non-GAAP Financial Measures
The Company reports financial results in accordance with
generally accepted accounting principles in the United States
(“GAAP”), however, the Company believes the evaluation of ongoing
operating results may be enhanced by a presentation of Adjusted
EBITDA, Adjusted EBITDA Margin, Adjusted Net Income and Adjusted
Net Income per Share, which are non-GAAP financial measures.
Although the Company provides guidance for adjusted EBITDA, it is
not able to provide guidance for net income, the most directly
comparable GAAP measure. Certain elements of the composition of net
income, including equity-based compensation, are not predictable,
making it impractical for us to provide guidance on net income or
to reconcile our adjusted EBITDA guidance to net income without
unreasonable efforts. For the same reasons, the Company is unable
to address the probable significance of the unavailable information
regarding net income, which could be material to future
results.
These non-GAAP financial measures are not intended to replace
financial performance measures determined in accordance with GAAP.
Rather, they are presented as supplemental measures of the
Company's performance that management believes may enhance the
evaluation of the Company's ongoing operating results. These
non-GAAP financial measures are not presented in accordance with
GAAP, and the Company’s computation of these non-GAAP financial
measures may vary from similar measures used by other companies.
These measures have limitations as an analytical tool and should
not be considered in isolation or as a substitute or alternative to
revenue, net income, operating income, cash flows from operating
activities, total indebtedness or any other measures of operating
performance, liquidity or indebtedness derived in accordance with
GAAP.
AirSculpt Technologies, Inc. and Subsidiaries |
Selected Consolidated Financial Data |
(Dollars in thousands) |
|
|
Three Months Ended |
|
Six Months Ended |
|
June 30, |
|
June 30, |
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
Revenue |
$ |
55,703 |
|
|
$ |
49,654 |
|
|
$ |
101,516 |
|
|
$ |
89,198 |
|
Operating expenses: |
|
|
|
|
|
|
|
Cost of service |
|
19,952 |
|
|
|
17,492 |
|
|
|
37,969 |
|
|
|
32,154 |
|
Selling, general and administrative |
|
27,893 |
|
|
|
26,010 |
|
|
|
51,775 |
|
|
|
50,177 |
|
Depreciation and amortization |
|
2,514 |
|
|
|
1,962 |
|
|
|
4,850 |
|
|
|
3,848 |
|
Loss/(gain) on disposal of long-lived assets |
|
(18 |
) |
|
|
227 |
|
|
|
(202 |
) |
|
|
227 |
|
Total operating expenses |
|
50,341 |
|
|
|
45,691 |
|
|
|
94,392 |
|
|
|
86,406 |
|
Income from operations |
|
5,362 |
|
|
|
3,963 |
|
|
|
7,124 |
|
|
|
2,792 |
|
Interest expense, net |
|
1,891 |
|
|
|
1,559 |
|
|
|
3,626 |
|
|
|
3,051 |
|
Pre-tax net income/(loss) |
|
3,471 |
|
|
|
2,404 |
|
|
|
3,498 |
|
|
|
(259 |
) |
Income tax
expense/(benefit) |
|
1,695 |
|
|
|
1,821 |
|
|
|
1,736 |
|
|
|
(149 |
) |
Net income/(loss) |
$ |
1,776 |
|
|
$ |
583 |
|
|
$ |
1,762 |
|
|
$ |
(110 |
) |
|
|
|
|
|
|
|
|
Income/(loss) per share of
common stock |
|
|
|
|
|
|
|
Basic |
$ |
0.03 |
|
|
$ |
0.01 |
|
|
$ |
0.03 |
|
|
$ |
(0.00 |
) |
Diluted |
$ |
0.03 |
|
|
$ |
0.01 |
|
|
$ |
0.03 |
|
|
$ |
(0.00 |
) |
Weighted average shares
outstanding |
|
|
|
|
|
|
|
Basic |
|
56,753,498 |
|
|
|
55,640,154 |
|
|
|
56,599,291 |
|
|
|
55,640,154 |
|
Diluted |
|
58,511,766 |
|
|
|
58,360,685 |
|
|
|
58,095,736 |
|
|
|
55,640,154 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AirSculpt Technologies, Inc. and Subsidiaries |
Selected Financial and Operating Data |
(Dollars in thousands, except per case
amounts) |
|
|
June 30, |
|
December 31, |
|
2023 |
|
2022 |
Balance Sheet Data (at
period end): |
|
|
|
Cash and cash equivalents |
$ |
20,779 |
|
|
$ |
9,616 |
|
Total current assets |
|
26,829 |
|
|
|
16,676 |
|
Total assets |
$ |
217,284 |
|
|
$ |
200,759 |
|
|
|
|
|
Current portion of long-term
debt |
$ |
2,125 |
|
|
$ |
2,125 |
|
Deferred revenue and patient
deposits |
|
4,271 |
|
|
|
2,358 |
|
Total current liabilities |
|
23,948 |
|
|
|
22,318 |
|
Long-term debt, net |
|
80,875 |
|
|
|
81,420 |
|
Total liabilities |
$ |
135,812 |
|
|
$ |
129,993 |
|
|
|
|
|
Total stockholders’ equity |
$ |
81,472 |
|
|
$ |
70,766 |
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Six Months Ended |
|
June 30, |
|
June 30, |
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
Cash Flow
Data: |
|
|
|
|
|
|
|
Net cash provided by (used
in): |
|
|
|
|
|
|
|
Operating activities |
$ |
12,236 |
|
|
$ |
10,398 |
|
|
$ |
18,455 |
|
|
$ |
17,478 |
|
Investing activities |
|
(2,161 |
) |
|
|
(1,865 |
) |
|
|
(5,976 |
) |
|
|
(6,139 |
) |
Financing activities |
|
(579 |
) |
|
|
(509 |
) |
|
|
(1,316 |
) |
|
|
(1,433 |
) |
|
Three Months Ended |
|
Six Months Ended |
|
June 30, |
|
June 30, |
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
Other
Data: |
|
|
|
|
|
|
|
Number of facilities |
|
25 |
|
|
|
19 |
|
|
|
25 |
|
|
|
19 |
|
Number of total procedure
rooms |
|
53 |
|
|
|
38 |
|
|
|
53 |
|
|
|
38 |
|
|
|
|
|
|
|
|
|
Cases |
|
4,186 |
|
|
|
3,691 |
|
|
|
7,826 |
|
|
|
6,847 |
|
Revenue per case |
$ |
13,307 |
|
|
$ |
13,453 |
|
|
$ |
12,972 |
|
|
$ |
13,027 |
|
Adjusted EBITDA (1) (3) |
$ |
14,612 |
|
|
$ |
13,977 |
|
|
$ |
24,068 |
|
|
$ |
22,919 |
|
Adjusted EBITDA margin
(2) |
|
26.2 |
% |
|
|
28.1 |
% |
|
|
23.7 |
% |
|
|
25.7 |
% |
(1) |
A reconciliation of this non-GAAP financial measure appears
below. |
(2) |
Defined as Adjusted EBITDA as
a percentage of revenue. |
(3) |
For the three months ended
June 30, 2023 and 2022, pre-opening de novo and relocation costs
were $1.4 million and $1.2 million, respectively. For the six
months ended June 30, 2023 and 2022, pre-opening de novo and
relocation costs were $2.7 million and $2.1 million,
respectively. |
|
|
|
|
|
Three Months Ended |
|
Six Months Ended |
|
June 30, |
|
June 30, |
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
Same-center Information
(1): |
|
|
|
|
|
|
|
Cases |
|
3,589 |
|
|
|
3,691 |
|
|
|
6,638 |
|
|
|
6,724 |
|
Case
growth |
|
(2.8) |
% |
|
N/A |
|
|
(1.3) |
% |
|
N/A |
Revenue
per case |
$ |
13,249 |
|
|
$ |
13,452 |
|
|
$ |
13,005 |
|
|
$ |
12,994 |
|
Revenue
per case growth |
|
(1.5) |
% |
|
N/A |
|
|
0.1 |
% |
|
N/A |
Number
of facilities |
|
19 |
|
|
|
19 |
|
|
|
18 |
|
|
|
18 |
|
Number
of total procedure rooms |
|
40 |
|
|
|
38 |
|
|
|
38 |
|
|
|
35 |
|
(1) |
For the three months ended June 30, 2023 and 2022,
we define same-center case and revenue growth as the growth in each
of our cases and revenue at facilities that have been owned and
operated since April 1, 2022. We define same-center facilities and
procedure rooms as facilities and procedure rooms that have been
owned or operated since April 1, 2022. |
|
For the six months ended
June 30, 2023 and 2022, we define same-center case and revenue
growth as the growth in each of our cases and revenue at facilities
that have been owned and operated since January 1, 2022. We define
same-center facilities and procedure rooms as facilities and
procedure rooms that have been owned or operated since January 1,
2022. |
|
AirSculpt Technologies, Inc. and Subsidiaries |
Reconciliation of Non-GAAP Financial Measures |
(Dollars in thousands) |
|
We report our financial results in accordance
with GAAP, however, management believes the evaluation of our
ongoing operating results may be enhanced by a presentation of
Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income and
Adjusted Net Income per Share, which are non-GAAP financial
measures.
We define Adjusted EBITDA as net income/(loss)
excluding depreciation and amortization, net interest expense,
income tax expense/(benefit), restructuring and related severance
costs, IPO related costs, (gain)/loss on disposal of long-lived
assets, and equity-based compensation.
We define Adjusted Net Income as net
income/(loss) excluding, restructuring and related severance costs,
IPO related costs, (gain)/loss on disposal of long-lived assets,
equity-based compensation and the tax effect of these
adjustments.
We include Adjusted EBITDA and Adjusted Net
Income because they are important measures on which our management
assesses and believes investors should assess our operating
performance. We consider Adjusted EBITDA and Adjusted Net Income to
be an important measure because they help illustrate underlying
trends in our business and our historical operating performance on
a more consistent basis. Adjusted EBITDA has limitations as an
analytical tool including: (i) Adjusted EBITDA does not
include results from equity-based compensation and
(ii) Adjusted EBITDA does not reflect interest expense on our
debt or the cash requirements necessary to service interest or
principal payments. Adjusted Net Income has limitations as an
analytical tool because it does not include results from
equity-based compensation.
We define Adjusted EBITDA Margin as Adjusted
EBITDA as a percentage of revenue. We define Adjusted Net Income
per Share as Adjusted Net Income divided by weighted average basic
and diluted shares. We included Adjusted EBITDA Margin and Adjusted
Net Income per Share because they are important measures on which
our management assesses and believes investors should assess our
operating performance. We consider Adjusted EBITDA Margin and
Adjusted Net Income per Share to be important measures because they
help illustrate underlying trends in our business and our
historical operating performance on a more consistent basis.
The following table reconciles Adjusted EBITDA
and Adjusted EBITDA Margin to net (loss)/income, the most directly
comparable GAAP financial measure:
|
Three Months Ended |
Six Months Ended |
|
June 30, |
|
June 30, |
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
Net income/(loss) |
$ |
1,776 |
|
|
$ |
583 |
|
|
$ |
1,762 |
|
|
$ |
(110 |
) |
Plus |
|
|
|
|
|
|
Equity-based compensation |
|
4,603 |
|
|
|
7,275 |
|
|
|
8,991 |
|
|
|
14,591 |
|
IPO related costs |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
731 |
|
Restructuring and related severance costs |
|
2,151 |
|
|
|
550 |
|
|
|
3,305 |
|
|
|
730 |
|
Depreciation and amortization |
|
2,514 |
|
|
|
1,962 |
|
|
|
4,850 |
|
|
|
3,848 |
|
Loss/(gain) on disposal of long-lived assets |
|
(18 |
) |
|
|
227 |
|
|
|
(202 |
) |
|
|
227 |
|
Interest expense, net |
|
1,891 |
|
|
|
1,559 |
|
|
|
3,626 |
|
|
|
3,051 |
|
Income tax expense/(benefit) |
|
1,695 |
|
|
|
1,821 |
|
|
|
1,736 |
|
|
|
(149 |
) |
Adjusted
EBITDA |
$ |
14,612 |
|
|
$ |
13,977 |
|
|
$ |
24,068 |
|
|
$ |
22,919 |
|
Adjusted EBITDA
Margin |
|
26.2 |
% |
|
|
28.1 |
% |
|
|
23.7 |
% |
|
|
25.7 |
% |
|
For the three months ended June 30, 2023 and 2022, pre-opening
de novo and relocation costs were $1.4 million and $1.2 million,
respectively. For the six months ended June 30, 2023 and 2022,
pre-opening de novo and relocation costs were $2.7 million and $2.1
million, respectively.
AirSculpt Technologies, Inc. and Subsidiaries |
Reconciliation of Non-GAAP Financial Measures |
(Dollars in thousands) |
|
The following table reconciles Adjusted Net
Income and Adjusted Net Income per Share to net loss, the most
directly comparable GAAP financial measure:
|
Three Months Ended |
|
Six Months Ended |
|
June 30, |
|
June 30, |
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
Net
income/(loss) |
$ |
1,776 |
|
|
$ |
583 |
|
|
$ |
1,762 |
|
|
$ |
(110 |
) |
Plus |
|
|
|
|
|
|
|
Equity-based compensation |
|
4,603 |
|
|
|
7,275 |
|
|
|
8,991 |
|
|
|
14,591 |
|
IPO related costs |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
731 |
|
Restructuring and related severance costs |
|
2,151 |
|
|
|
550 |
|
|
|
3,305 |
|
|
|
730 |
|
Loss/(gain) on disposal of long-lived assets |
|
(18 |
) |
|
|
227 |
|
|
|
(202 |
) |
|
|
227 |
|
Tax effect of adjustments |
|
(869 |
) |
|
|
(477 |
) |
|
|
(1,328 |
) |
|
|
(1,000 |
) |
Adjusted net
income |
$ |
7,643 |
|
|
$ |
8,158 |
|
|
$ |
12,528 |
|
|
$ |
15,169 |
|
|
|
|
|
|
|
|
|
Adjusted net income per share
of common stock (1) |
|
|
|
|
|
|
|
Basic |
$ |
0.13 |
|
|
$ |
0.15 |
|
|
$ |
0.22 |
|
|
$ |
0.27 |
|
Diluted |
$ |
0.13 |
|
|
$ |
0.14 |
|
|
$ |
0.22 |
|
|
$ |
0.26 |
|
Weighted average shares
outstanding |
|
|
|
|
|
|
|
Basic |
|
56,753,498 |
|
|
|
55,640,154 |
|
|
|
56,599,291 |
|
|
|
55,640,154 |
|
Diluted |
|
58,511,766 |
|
|
|
58,360,685 |
|
|
|
58,095,736 |
|
|
|
58,360,685 |
|
(1) |
Diluted Adjusted Net Income Per Share is computed by dividing
adjusted net income by the weighted-average number of shares of
common stock outstanding adjusted for the dilutive effect of all
potential shares of common stock. |
|
|
Investor ContactSteven Halper/Caroline
PaulManaging Directors, LifeSci
Advisorsinvestors@elitebodysculpture.com
Media ContactStephanie Evans GreeneChief
Marketing OfficerAirSculpt Technologies,
Inc.sevansgreene@elitebodysculpture.com
AirSculpt Technologies (NASDAQ:AIRS)
Historical Stock Chart
From Apr 2024 to May 2024
AirSculpt Technologies (NASDAQ:AIRS)
Historical Stock Chart
From May 2023 to May 2024